Characteristics and survival of patients with advanced cancer and p53 mutations

Characteristics and survival of patients with advanced cancer and p53 mutations

P53 mutations are associated with invasive tumors in mouse models. We assessed the p53mutations and survival in patients with advanced cancer treated in the Phase I Program. Of 691 tested patients, 273 (39.5%) had p53 mutations. Patients with p53 mutations were older (p<.0001) and had higher numb...

Full description

Bibliographic Details
Main Authors:	Said, Rabih, Ye, Yang, Hong, David S., Janku, Filip, Fu, Siqing, Naing, Aung, Wheler, Jennifer J., Kurzrock, Razelle, Thomas, Christoforos, Palmer, Gary A., Hess, Kenneth R., Aldape, Kenneth, Tsimberidou, Apostolia M.
Format:	Online
Language:	English
Published:	Impact Journals LLC 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116527/

Similar Items

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
by: Said, Rabih, et al.
Published: (2014)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
by: Said, Rabih, et al.
Published: (2013)

A pilot study of temsirolimus and body composition
by: Veasey-Rodrigues, Heloisa, et al.
Published: (2013)

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
by: Hou, Ming-Mo, et al.
Published: (2014)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
by: El-Osta, Hazem, et al.
Published: (2011)

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
by: Subbiah, Ishwaria M., et al.
Published: (2013)

PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
by: Janku, Filip, et al.
Published: (2011)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
by: Falchook, Gerald S., et al.
Published: (2014)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
by: Piha-Paul, Sarina A., et al.
Published: (2014)

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
by: Wheler, Jennifer, et al.
Published: (2013)

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
by: Janku, Filip, et al.
Published: (2012)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
by: Wheler, Jennifer J., et al.
Published: (2014)

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing
by: Janku, Filip, et al.
Published: (2014)

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy
by: Tsimberidou, Apostolia M, et al.
Published: (2015)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
by: Wheler, Jennifer, et al.
Published: (2013)

KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors
by: Garrido-Laguna, Ignacio, et al.
Published: (2012)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
by: Subbiah, Ishwaria M., et al.
Published: (2015)

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors
by: Tang, Chad, et al.
Published: (2013)

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience
by: Corrales-Medina, Fernando F., et al.
Published: (2014)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
by: Naing, Aung, et al.
Published: (2013)

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
by: Liu, Xiaochun, et al.
Published: (2016)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
by: Jardim, Denis L., et al.
Published: (2014)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
by: Fu, Siqing, et al.
Published: (2015)

Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications
by: Jiang, Yunyun, et al.
Published: (2013)

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
by: Falchook, Gerald S., et al.
Published: (2013)

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
by: Hou, Ming-Mo, et al.
Published: (2016)

Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors.
by: Yunyun Jiang, et al.

Novel Secondary Somatic Mutations in Ewing's Sarcoma and Desmoplastic Small Round Cell Tumors
by: Jiang, Yunyun, et al.
Published: (2014)

A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R): Implications for Inhibition of the IGF-1R signal
by: Janku, Filip, et al.
Published: (2013)

Castleman’s disease and sarcoidosis, a rare association resulting in a “mixed” response: a case report
by: Mohammed, Anwarullah, et al.
Published: (2015)

Androgen receptors beyond prostate cancer: an old marker as a new target
by: Munoz, Javier, et al.
Published: (2014)

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
by: Janku, Filip, et al.
Published: (2015)

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
by: Janku, Filip, et al.
Published: (2015)

Challenges and perspective of drug repurposing strategies in early phase clinical trials
by: Kato, Shumei, et al.
Published: (2015)

Multiple gene aberrations and breast cancer: lessons from super-responders
by: Wheler, Jennifer J., et al.
Published: (2015)

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance
by: Wheler, Jennifer, et al.
Published: (2015)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors
by: Wheler, Jennifer J., et al.
Published: (2016)

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms
by: Wheler, Jennifer J., et al.
Published: (2014)

Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors
by: Aung Naing, James M. Reuben, Luis H. Camacho, Hui Gao, Bang-Ning Lee, Evan N. Cohen, Claire Verschraegen, Saneese Stephen, Joann Aaron, David Hong, Jennifer Wheler, Razelle Kurzrock
Published: (2011-01-01)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
by: Kurzrock, Razelle, et al.
Published: (2015)